VEEV

Veeva Systems Inc.

Healthcare, TMT


Presented:12/11/2013
Price:$38.31
Cap:$4.68B
Current Price:$210.00
Cap:$34.01B

Presented

Date12/11/2013
Price$38.31
Market Cap$4.68B
Ent Value$4.41B
P/E Ratio155.88x
Book Value$2.92
Div YieldN/A
Shares O/S122.25M
Ave Daily Vol1,080,000
Short Int0.45%

Current

Price$210.00
Market Cap$34.01B
Veeva Systems Inc. provides industry-specific cloud-based software solutions for the life sciences industry in North America, Europe, and the Asia Pacific. The company’s solutions enable pharmaceutical and other life sciences companies to realize the benefits of cloud-based architectures and mobile applications for their critical business functions. Its industry cloud solutions include Veeva CRM for customer relationship management that enables physician-facing employees, such as pharmaceutical sales representatives, key account managers, and scientific liaisons to manage, track, and optimize interactions with healthcare providers in various communication channels utilizing a single integrated solution; and Veeva Vault, a cloud-based content management and collaboration solution for its customers to manage content-centric processes in various departments within a life sciences company, including clinical trials, quality management, manufacturing, sales, and marketing. The company’s industry cloud solutions comprise Veeva Network, a cloud-based customer master solution to help life sciences companies in creating and maintaining a record of the healthcare professionals and healthcare organizations with which they interact. In addition, it offers professional and support services. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was founded in 2007 and is headquartered in Pleasanton, California.

Highlights

The presenter is bearish on the outlook for shares of Veeva (VEEV), the provider of cloud-based customer relationship management (CRM) and regulated content management services to the global pharmaceutical and biotechnology companies. His short thesis is based on the potential for VEEV to underperform Street expectations in the coming years, as billings (a predictor of revenue growth) decelerate and competition increases.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.